Michael Mogerman, MD
Psychiatry · Williamsville, NYNPI 1457305773
Payments from drug & device makers
Across 234 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$875
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$614
- Lundbeck LLC$590
- Takeda Pharmaceuticals U.S.A., Inc.$482
- Otsuka America Pharmaceutical, Inc.$263
- Bausch Health US, LLC$197
- plus $635 from 11 others
What the payments were for
- Food & beverage$3,57298%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $875 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $614 |
| Lundbeck LLC | 35 | $590 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $482 |
| Otsuka America Pharmaceutical, Inc. | 17 | $263 |
| Bausch Health US, LLC | 11 | $197 |
| Almatica Pharma LLC | 8 | $147 |
| Alkermes, Inc. | 6 | $126 |
| Vanda Pharmaceuticals Inc. | 5 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Merck | 4 | $56 |
| Johnson & Johnson | 3 | $52 |
| Eisai Inc. | 2 | $33 |
| Neos Therapeutics, LP | 2 | $24 |
| Shire North American Group Inc | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
How this compares
$3,656 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 36 | $53,835 |
| CaplytaLumateperone Tosylate | 26 | $47,023 |
| RexultiBrexpiprazole | 20 | $34,346 |
| TrintellixVortioxetine Hydrobromide | 57 | $30,802 |
| ValiumDiazepam | 11 | $20,487 |
| Chlorpromazine Hcl | 16 | $8,215 |
| Quetiapine Fumarate | 170 | $5,481 |
| Lurasidone Hcl | 17 | $4,812 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 71 | $2,833 |
| Fluphenazine Hcl | 17 | $2,808 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 38 | $2,470 |
| Buspirone Hcl | 75 | $2,190 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 58 | $2,140 |
| Lorazepam | 257 | $2,018 |
| Ramelteon | 17 | $1,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $875 | $53,83536 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $614 | $47,02326 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $263 | $34,34620 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $482 | $30,80257 claims |
| Almatica Pharma LLCSertraline Hcl | $147 | $1,825121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Williamsville
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.